Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 62 articles: HTML format

Single Articles

June 2024
1. KARA-ALI GH, Cano L, Dion S, Imerzoukene G, et al
   Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation.
   Int J Cancer. 2024;154:1999-2013.
   PubMed     Abstract available
   
   
   May 2024
2. GERBER TS, Ridder DA, Goeppert B, Brobeil A, et al
   N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
   Int J Cancer. 2024;154:1857-1868.
   PubMed     Abstract available
   
   
   February 2024
3. QIN XY, Shirakami Y, Honda M, Yeh SH, et al
   Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
   Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893.
   PubMed     Abstract available
   
   
   
4. YU Z, Bai X, Zhou R, Ruan G, et al
   Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019.
   Int J Cancer. 2024;154:615-625.
   PubMed     Abstract available
   
   
   
5. XU FQ, Xu QY, Zhu ZJ, Jin L, et al
   Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study.
   Int J Cancer. 2024;154:530-537.
   PubMed     Abstract available
   
   
   
6. JIANG L, Zhao N, Xu M, Pei J, et al
   Incidence trends of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: An age-period-cohort analysis.
   Int J Cancer. 2024;154:465-476.
   PubMed     Abstract available
   
   
   
7. BARUPAL DK, Ramos ML, Florio AA, Wheeler WA, et al
   Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case-control study within the ATBC cohort.
   Int J Cancer. 2024;154:454-464.
   PubMed     Abstract available
   
   
   January 2024
8. ZHAO G, Shi X, Zhang L, Liang H, et al
   Comment on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
   Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34796.
   PubMed    
   
   
   
9. KIM MN, Zhang X, Ahn SH
   Reply to: Comments on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
   Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34797.
   PubMed    
   
   
   November 2023
10. ROSSARI F, Tada T, Suda G, Shimose S, et al
    alpha-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Int J Cancer. 2023 Nov 23. doi: 10.1002/ijc.34799.
    PubMed     Abstract available
    
    
    October 2023
11. SOMMERHAUSER G, Karthaus M, Kurreck A, Ballhausen A, et al
    Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34760.
    PubMed     Abstract available
    
    
    
12. SIRIRUNGREUNG A, Lee PC, Hu YH, Liew Z, et al
    Maternal medically diagnosed infection and antibiotic prescription during pregnancy and risk of childhood cancer: A population-based cohort study in Taiwan, 2004 to 2015.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34744.
    PubMed     Abstract available
    
    
    August 2023
13. HA Y, Lim J, Chon YE, Kim MN, et al
    Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients.
    Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34704.
    PubMed     Abstract available
    
    
    July 2023
14. SHANG Y, Morioka T, Daino K, Nakayama T, et al
    Ionizing radiation promotes, whereas calorie restriction suppresses, NASH and hepatocellular carcinoma in mice.
    Int J Cancer. 2023 Jul 17. doi: 10.1002/ijc.34651.
    PubMed     Abstract available
    
    
    
15. KIM MN, Han K, Yoo J, Hwang SG, et al
    Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
    Int J Cancer. 2023 Jul 13. doi: 10.1002/ijc.34637.
    PubMed     Abstract available
    
    
    March 2023
16. HEMMINKI K, Sundquist K, Sundquist J, Forsti A, et al
    Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers.
    Int J Cancer. 2023;152:1107-1114.
    PubMed     Abstract available
    
    
    
17. LI ZY, Tan YT, Liu DK, Gao LF, et al
    Cumulative consumption of tea is associated with lower risk of liver cancer: Updated results from the Shanghai Women's Health Study.
    Int J Cancer. 2023;152:1115-1123.
    PubMed     Abstract available
    
    
    
18. VANDERBORGHT B, De Muynck K, Gijbels E, Lefere S, et al
    Transient Kupffer cell depletion and subsequent replacement by infiltrating monocyte-derived cells does not alter the induction or progression of hepatocellular carcinoma.
    Int J Cancer. 2023 Mar 13. doi: 10.1002/ijc.34505.
    PubMed     Abstract available
    
    
    
19. PETRICK JL, Florio AA, Zen J, Wang Y, et al
    Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL-HBV and REVEAL-HCV Cohort Studies.
    Int J Cancer. 2023 Mar 6. doi: 10.1002/ijc.34492.
    PubMed     Abstract available
    
    
    February 2023
20. XIA C, Yu XQ, Chen W
    Measuring population-level cure patterns for cancer patients in the United States.
    Int J Cancer. 2023;152:738-748.
    PubMed     Abstract available
    
    
    August 2022
21. ZHANG P, Ono A, Fujii Y, Hayes CN, et al
    The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34247.
    PubMed     Abstract available
    
    
    July 2022
22. HANG D, Yang X, Lu J, Shen C, et al
    Untargeted plasma metabolomics for risk prediction of hepatocellular carcinoma: A prospective study in two Chinese cohorts.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34229.
    PubMed     Abstract available
    
    
    
23. COMMANDER SJ, Cerullo M, Arjunji N, Leraas HJ, et al
    Improved Survival and Higher Rates of Surgical Resection Associated with Hepatocellular Carcinoma in Children as Compared to Young Adults.
    Int J Cancer. 2022 Jul 16. doi: 10.1002/ijc.34215.
    PubMed     Abstract available
    
    
    
24. WEN Q, Chan KH, Shi K, Lv J, et al
    Tobacco smoking and solid fuels for cooking and risk of liver cancer: A prospective cohort study of 0.5 million Chinese adults.
    Int J Cancer. 2022;151:181-190.
    PubMed     Abstract available
    
    
    
25. FU P, Gong B, Li H, Luo Q, et al
    Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma.
    Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34201.
    PubMed     Abstract available
    
    
    June 2022
26. NIGER M, Nichetti F, Casadei-Gardini A, Rizzato MD, et al
    Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34182.
    PubMed     Abstract available
    
    
    
27. ZHENG G, Bouamar H, Cserhati M, Zeballos CR, et al
    Integrin alpha 6 (ITGA6) is upregulated and drives hepatocellular carcinoma progression through integrin alpha6beta4 complex.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34146.
    PubMed     Abstract available
    
    
    May 2022
28. WU H, Zheng X, Pan T, Yang X, et al
    Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34118.
    PubMed     Abstract available
    
    
    
29. YUN J, Kim YS, Heo MJ, Kim MJ, et al
    ERalpha inhibits mesenchymal and amoeboidal movement of liver cancer cell via Galpha12.
    Int J Cancer. 2022;150:1690-1705.
    PubMed     Abstract available
    
    
    
30. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
    Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Int J Cancer. 2022;150:1537-1548.
    PubMed     Abstract available
    
    
    April 2022
31. CHEN S, Gao Y, Wang Y, Daemen T, et al
    The Combined Signatures of Hypoxia and Cellular Landscape Provides a Prognostic and Therapeutic Biomarker in HBV-Related Hepatocellular Carcinoma.
    Int J Cancer. 2022 Apr 25. doi: 10.1002/ijc.34045.
    PubMed     Abstract available
    
    
    
32. LIAO W, Du J, Wang Z, Feng Q, et al
    The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34040.
    PubMed     Abstract available
    
    
    
33. HEMMINKI K, Tichanek F, Forsti A, Hemminki O, et al
    Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34031.
    PubMed     Abstract available
    
    
    March 2022
34. VAZ J, Midlov P, Eilard MS, Eriksson B, et al
    Targeting population groups with heavier burden of hepatocellular carcinoma incidence: a nationwide descriptive epidemiological study in Sweden.
    Int J Cancer. 2022 Mar 7. doi: 10.1002/ijc.33993.
    PubMed     Abstract available
    
    
    February 2022
35. SEFRIOUI D, Verdier V, Savoye-Collet C, Beaussire L, et al
    Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
    Int J Cancer. 2022;150:532-541.
    PubMed     Abstract available
    
    
    December 2021
36. KIM MN, Han K, Yoo J, Ha Y, et al
    Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study.
    Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33920.
    PubMed     Abstract available
    
    
    
37. TANAKA H, Horioka K, Hasebe T, Sawada K, et al
    Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor-platelet interactions.
    Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33915.
    PubMed     Abstract available
    
    
    
38. RUTHERFORD MJ, Arnold M, Bardot A, Ferlay J, et al
    Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
    Int J Cancer. 2021;149:2020-2031.
    PubMed     Abstract available
    
    
    
39. RIDDER DA, Weinmann A, Schindeldecker M, Urbansky LL, et al
    Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma.
    Int J Cancer. 2021 Dec 11. doi: 10.1002/ijc.33898.
    PubMed     Abstract available
    
    
    
40. SO R, Chen J, Mehta AJ, Liu S, et al
    Long-term exposure to air pollution and liver cancer incidence in six European cohorts.
    Int J Cancer. 2021;149:1887-1897.
    PubMed     Abstract available
    
    
    November 2021
41. STEPIEN M, Lopez-Nogueroles M, Lahoz A, Kuhn T, et al
    Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
    Int J Cancer. 2021 Nov 29. doi: 10.1002/ijc.33885.
    PubMed     Abstract available
    
    
    
42. MOEHLER M, Folprecht G, Heinemann V, Holch JW, et al
    Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
    Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.
    PubMed     Abstract available
    
    
    September 2021
43. XU L, Leng C, Chen L, Dong H, et al
    Hypothyroidism is a Predictive Factor of Superior Anti-tumor Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33813.
    PubMed     Abstract available
    
    
    August 2021
44. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    PubMed     Abstract available
    
    
    July 2021
45. CAO M, Huang W, Chen Y, Li G, et al
    Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through beta-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
    Int J Cancer. 2021;149:460-472.
    PubMed     Abstract available
    
    
    
46. ZHUO Z, Miao L, Hua W, Chen H, et al
    Genetic variations in nucleotide excision repair (NER) pathway genes and hepatoblastoma susceptibility.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33722.
    PubMed     Abstract available
    
    
    June 2021
47. WANG L, Long J, Chen H, Sun S, et al
    Manipulation of focal Wnt activity via synthetic cells in a double-humanized zebrafish model of tumorigenesis.
    Int J Cancer. 2021;148:2815-2824.
    PubMed     Abstract available
    
    
    May 2021
48. LONG L, Liu X, Jin L, Simon T, et al
    Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men.
    Int J Cancer. 2021 May 24. doi: 10.1002/ijc.33699.
    PubMed     Abstract available
    
    
    April 2021
49. MAYEN AL, Aglago EK, Knaze V, Cordova R, et al
    Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: a multinational cohort study.
    Int J Cancer. 2021 Apr 25. doi: 10.1002/ijc.33612.
    PubMed     Abstract available
    
    
    
50. LU L, Xing K, Wei W, Ling Y, et al
    Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33609.
    PubMed     Abstract available
    
    
    
51. ZHU HB, Xu D, Ye M, Sun L, et al
    Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
    Int J Cancer. 2021;148:1717-1730.
    PubMed     Abstract available
    
    
    March 2021
52. WASHINGTON MK, Goldberg RM, Chang GJ, Limburg P, et al
    Diagnosis of digestive system tumours.
    Int J Cancer. 2021;148:1040-1050.
    PubMed     Abstract available
    
    
    November 2020
53. HEO MJ, Kang SH, Kim YS, Lee JM, et al
    UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
    Int J Cancer. 2020;147:2550-2563.
    PubMed     Abstract available
    
    
    
54. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    PubMed     Abstract available
    
    
    October 2020
55. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available
    
    
    
56. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    PubMed     Abstract available
    
    
    September 2020
57. FRENCH B, Sadakane A, Cologne J, Mabuchi K, et al
    Misclassification of primary liver cancer in the Life Span Study of atomic bomb survivors.
    Int J Cancer. 2020;147:1294-1299.
    PubMed     Abstract available
    
    
    
58. GIANNINI V, Rosati S, Defeudis A, Balestra G, et al
    Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33271.
    PubMed     Abstract available
    
    
    August 2020
59. ZHONG GC, Wang K, Peng Y, Shivappa N, et al
    Dietary inflammatory index and incidence of and death from primary liver cancer: A prospective study of 103,902 American adults.
    Int J Cancer. 2020;147:1050-1058.
    PubMed     Abstract available
    
    
    July 2020
60. LINDNER AU, Carberry S, Monsefi N, Barat A, et al
    Systems analysis of protein signatures predicting Cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenografts models of metastatic colorectal cancer.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33226.
    PubMed     Abstract available
    
    
    February 2020
61. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    PubMed     Abstract available
    
    
    December 2019
62. WOLSTENHOLME J, Fusco F, Gray AM, Moschandreas J, et al
    Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    Int J Cancer. 2019 Dec 16. doi: 10.1002/ijc.32828.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.